Cellectis (CLLS) News Today $1.87 -0.04 (-2.09%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.comNovember 13, 2024 | americanbankingnews.comCellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.comStockNews.com started coverage on Cellectis in a report on Wednesday. They issued a "sell" rating on the stock.November 13, 2024 | marketbeat.comPromising Partnership and Pipeline Propel Cellectis SA to a Buy RatingNovember 8, 2024 | markets.businessinsider.comCellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comCellectis SA: Strategic Advancements and Financial Strengths Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comCellectis price target lowered to $5 from $7 at BarclaysNovember 7, 2024 | markets.businessinsider.comCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingNovember 5, 2024 | globenewswire.comCellectis S.A. (CLLS) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comCellectis (NASDAQ:CLLS) Announces Earnings ResultsCellectis (NASDAQ:CLLS - Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. During the same period in the previous year, the firm posted ($0.31) EPS.November 5, 2024 | marketbeat.comBarclays Has Lowered Expectations for Cellectis (NASDAQ:CLLS) Stock PriceBarclays decreased their price objective on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Tuesday.November 5, 2024 | marketbeat.comStockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)StockNews.com started coverage on shares of Cellectis in a research report on Tuesday. They issued a "sell" rating on the stock.November 5, 2024 | marketbeat.comCellectis Provides Business Updates and Financial Results for Third Quarter 2024November 4, 2024 | globenewswire.comCellectis SA to Unveil Q3 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comCellectis (CLLS) Scheduled to Post Earnings on MondayCellectis (NASDAQ:CLLS) will be releasing earnings after the market closes on Monday, November 4, Zacks reports.October 31, 2024 | marketbeat.comCellectis to Report Third Quarter 2024 Financial Results on November 4, 2024October 30, 2024 | globenewswire.comCellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.comStockNews.com started coverage on Cellectis in a research report on Monday. They set a "sell" rating on the stock.October 28, 2024 | marketbeat.comCellectis Presents New Gene-Editing BreakthroughsOctober 22, 2024 | msn.comCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressOctober 22, 2024 | finance.yahoo.comCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressOctober 22, 2024 | globenewswire.comCellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.comStockNews.com started coverage on Cellectis in a research report on Sunday. They issued a "sell" rating for the company.October 20, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.comStockNews.com started coverage on Cellectis in a report on Saturday. They issued a "sell" rating for the company.October 12, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Stock Crosses Below 200-Day Moving Average of $2.41Cellectis (NASDAQ:CLLS) Stock Price Passes Below Two Hundred Day Moving Average of $2.41September 26, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.comStockNews.com initiated coverage on shares of Cellectis in a research report on Thursday. They issued a "sell" rating on the stock.September 26, 2024 | marketbeat.comGubra A/S (PI3.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comCellectis S.A. (CMVLF)September 22, 2024 | finance.yahoo.comCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetySeptember 3, 2024 | globenewswire.comCellectis S.A. (0WA2.IL)September 2, 2024 | uk.finance.yahoo.comCellectis S.A. (NASDAQ:CLLS) Sees Significant Drop in Short InterestCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 395,400 shares, a decline of 10.3% from the July 31st total of 440,700 shares. Based on an average daily volume of 53,700 shares, the days-to-cover ratio is currently 7.4 days.September 1, 2024 | marketbeat.comCellectis: Cheap With Promising But Speculative Cancer TherapiesAugust 30, 2024 | seekingalpha.comCellectis SA (ZVAA.DU)August 28, 2024 | uk.finance.yahoo.comCellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid TumorsAugust 26, 2024 | globenewswire.comBaillie Gifford & Co. Sells 119,618 Shares of Cellectis S.A. (NASDAQ:CLLS)Baillie Gifford & Co. reduced its position in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 14.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 707,630 shares of the biotechnology company's stock after selling 119,61August 26, 2024 | marketbeat.comStockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)StockNews.com initiated coverage on shares of Cellectis in a research note on Sunday. They issued a "sell" rating on the stock.August 25, 2024 | marketbeat.comCellectis SA: Strong Buy Rating on Robust Pipeline and Financial StabilityAugust 10, 2024 | markets.businessinsider.comCellectis Non-GAAP EPS of -$0.22 beats by $0.09, revenue of $9.5M misses by $0.2MAugust 8, 2024 | msn.comCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical OfficerAugust 7, 2024 | globenewswire.comCLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024August 7, 2024 | markets.businessinsider.comCellectis GAAP EPS of -$0.28 beats by $0.02, revenue of $9.5M beats by $5.77MAugust 6, 2024 | msn.comCellectis Provides Financial Results for the Second Quarter 2024August 6, 2024 | globenewswire.comFDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 3, 2024 | stockhouse.comCellectis Inc.: FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 2, 2024 | finanznachrichten.deCellectis Gets Orphan Designation for Drug Used in Cancer TreatmentAugust 2, 2024 | marketwatch.comFDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL TreatmentAugust 1, 2024 | finance.yahoo.comFDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 1, 2024 | globenewswire.comFDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) TreatmentJuly 25, 2024 | globenewswire.comCellectis Reports Results from Shareholders Meeting Held on June 28, 2024June 28, 2024 | globenewswire.comCellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingJune 20, 2024 | globenewswire.comShort Interest in Cellectis S.A. (NASDAQ:CLLS) Decreases By 16.8%Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large decline in short interest in May. As of May 31st, there was short interest totalling 424,200 shares, a decline of 16.8% from the May 15th total of 509,900 shares. Based on an average daily volume of 46,700 shares, the short-interest ratio is presently 9.1 days.June 16, 2024 | marketbeat.comCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsJune 12, 2024 | globenewswire.comCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaJune 4, 2024 | globenewswire.com Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up. CLLS Media Mentions By Week CLLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼0.720.55▲Average Medical News Sentiment CLLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼41▲CLLS Articles Average Week Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MGTX News AMLX News AKBA News FDMT News CYRX News DSGN News VALN News CCCC News ALVO News VYGR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLLS Stock Alerts